Physician profile
James Hall
NPI 1164800892
$3,090.58
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $587 · 2021: $609 · 2022: $13.49 · 2023: $468 · 2024: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $997 · Food and Beverage: $369 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $997.00 |
| Food and Beverage | $369.45 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,029.13 | 2023-2024 | |
| Seagen INC. | $577.68 | 2019-2021 | |
| Astellas Pharma US INC | $529.53 | 2020-2023 | |
| Pfizer INC. | $168.67 | 2020-2023 | |
| Rigel Pharmaceuticals, INC. | $109.46 | 2020-2023 | Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $109.01 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $104.32 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $91.88 | 2021 | |
| Beigene USA, INC. | $79.51 | 2020 | |
| Janssen Biotech, INC. | $74.27 | 2023 | Darzalex, Tecvayli, Erleada |
| Amgen INC. | $43.14 | 2023 | Kyprolis, Lumakras |
| Astrazeneca Pharmaceuticals LP | $39.48 | 2023 | Calquence |
| Novo Nordisk INC | $25.23 | 2021-2022 | |
| Genzyme Corporation | $24.73 | 2021 | |
| Stemline Therapeutics INC. | $20.57 | 2023 | Orserdu |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $19.91 | 2023 | Krazati |
| Puma Biotechnology, INC. | $15.35 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.79 | 2023 | Eliquis |
| Merck Sharp & Dohme LLC | $13.92 | 2023 | Keytruda, Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.